Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GNUV203
- Development stage
- Preclinical
- Lead developer
- Genuv
01
Overview
GNUV203 is an investigational biologic therapy currently in early-stage development by Genuv, a clinical-stage biotechnology company based in South Korea. Positioned within Genuv's oncology pipeline, GNUV203 is intended for the treatment of various solid tumors. While the company has disclosed targets for other assets in the same series (such as PD-1 for GNUV201 and CCR8 for GNUV202), the specific molecular target and mechanism of action for GNUV203 remain proprietary and undisclosed. The asset is being developed using Genuv's proprietary antibody discovery platforms, which focus on identifying novel therapeutic candidates for immuno-oncology and neurodegenerative diseases.
Beyond the preview
Go deeper on GNUV203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GNUV203.